SCHEDULE: Sonic Fund II Boosts Fennec Pharma Stake to 8.2%
Beneficial Ownership Report
Sonic Fund II, L.P., along with Sonic GP LLC and Lawrence Kam, reported an aggregate beneficial ownership of 8.2% of Fennec Pharmaceuticals Inc.'s common stock as of December 31, 2025.
Summary
- Reporting persons, Sonic Fund II, L.P., Sonic GP LLC, and Lawrence Kam, collectively beneficially own 2,799,959 shares of Fennec Pharmaceuticals Inc. common stock.
- This represents 8.2% of the company's outstanding common stock.
- The ownership is based on 34,153,496 shares outstanding as of November 17, 2025, as reported in the Issuer's Prospectus Supplement.
- The filing is an Amendment No. 3 to Schedule 13G.
- Lawrence Kam holds sole voting and dispositive power over 190,202 shares and shared power over 2,607,357 shares.
- Sonic Fund II, L.P. and Sonic GP LLC share voting and dispositive power over 2,607,357 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as an increased stake by an institutional investor like Sonic Fund II suggests growing confidence in Fennec Pharmaceuticals' value proposition and future performance.
Positives
- Increased institutional ownership by Sonic Fund II, L.P. and its affiliates, signaling confidence in Fennec Pharmaceuticals Inc.
- The reporting group now holds a significant 8.2% stake, indicating a notable investment position.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that an increase in institutional ownership, particularly by an investment fund, can often be interpreted as a positive signal within the pharmaceutical industry, suggesting confidence in the company's pipeline, market position, or future prospects, especially for a company like Fennec Pharmaceuticals.
Stakeholder Impact
- Shareholders: May view the increased institutional ownership as a positive indicator of confidence in the company's future.
- Company Management: Could see this as validation of their strategy and potentially a more stable shareholder base.
Key Dates
| Date | Description |
|---|---|
| 2023-12-15 | Date of Issuer's Prospectus Supplement reporting shares outstanding. |
| 2025-11-17 | Date as of which 34,153,496 shares were outstanding. |
| 2025-11-18 | Date the Issuer's Prospectus Supplement was filed with the SEC. |
| 2025-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2026-02-17 | Filing date of the Schedule 13G Amendment No. 3. |
Keywords
Fennec Pharmaceuticals, Sonic Fund II, Lawrence Kam, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.